Skip to Content
Merck

SML0408

Carboxyamidotriazole

≥98% (HPLC)

Synonym(s):

5-Amino-1-[[3,5-Dichloro-4-(4-chlorobenzoyl)phenyl]meth yl]-1H-1,2,3-triazole-4-carboxamide, CAI, L-651582

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H12Cl3N5O2
CAS Number:
99519-84-3
Molecular Weight:
424.67
NACRES:
NA.77
PubChem Substance ID:
329825403
UNSPSC Code:
12352200
MDL number:
MFCD00866325
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL (clear solution)

storage temp.

2-8°C

SMILES string

NC(=O)c1nnn(Cc2cc(Cl)c(c(Cl)c2)C(=O)c3ccc(Cl)cc3)c1N

InChI

1S/C17H12Cl3N5O2/c18-10-3-1-9(2-4-10)15(26)13-11(19)5-8(6-12(13)20)7-25-16(21)14(17(22)27)23-24-25/h1-6H,7,21H2,(H2,22,27)

InChI key

WNRZHQBJSXRYJK-UHFFFAOYSA-N

Related Categories

Biochem/physiol Actions

Carboxyamidotriazole (CAI) is a non-cytotoxic anticancer drug. It exhibits anti-inflammatory properties and reduces the release of proinflammatory cytokines. CAI prevents the proliferation and invasive behavior of a variety of human cancer cell types and endothelial cells in vitro and in vivo. It is used to treat several acute and chronic inflammation models, like adjuvant arthritis and inflammatory bowel diseases (IBD). CAI blocks tumor cell proliferation and stimulates cell apoptosis in vitro.
Carboxyamidotriazole (L-651582) is an orally active calcium channel blocker. Carboxyamidotriazole blocks intracellular and mitochondrial calcium entry and flux, resulting in inhibition of cell proliferation, calcium-release-activated calcium channel (CRAC) function, and maintenance of mitochondrial membrane potential.
Carboxyamidotriazole is a calcium channel blocker/calcium flux inhibitor; inhibits CRAC channel function.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000127864
0000127865
0000126384
0000043954
0000043955

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hui Song et al.
Frontiers in microbiology, 8, 1419-1419 (2017-08-12)
Codon usage bias plays an important role in shaping genomes and genes in unicellular species and multicellular species. Here, we first analyzed codon usage bias in seven
Andreia S P Sousa et al.
Scientific reports, 9(1), 3115-3115 (2019-03-01)
This study aims to: (1) to compare 2 methods of assessing the timing of medium latency responses (MLR), in regard to intrasession reliability and mean values, in subjects with and without chronic ankle instability (CAI), and (2) to analyze the
Kevin Deschamps et al.
Clinical biomechanics (Bristol, Avon), 54, 1-7 (2018-03-05)
Investigate differences in multi-segment foot kinematics between controls and participants with chronic ankle instability during running with a midfoot striking pattern and to evaluate the effect of Low-Dye and High-Dye taping. Three-dimensional multi-segment foot kinematics of 12 controls and 15
Lars P J Cruysberg et al.
Retina (Philadelphia, Pa.), 25(8), 1022-1031 (2005-12-13)
To evaluate the human transscleral diffusion and intravitreal delivery of carboxyamido-triazole (CAI) and 2-Methoxyestradiol (2ME2). The transscleral diffusion of two retinal antiangiogenic molecules, CAI and 2ME2, was measured in vitro to assess their potential transscleral delivery. Varying concentrations and different
Fabienne Largey et al.
Neurology(R) neuroimmunology & neuroinflammation, 6(6) (2019-09-27)
To investigate the effects of natalizumab (NAT) treatment on intrathecally produced antiviral antibodies in MS. We performed a longitudinal, observational study analyzing both serum and CSF samples collected before and during NAT treatment for antibodies against measles, rubella, mumps, influenza
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service